RT @septian: Just published in Lancet Infectious Diseases: Sinovac phase 1/2 results Safety, tolerability & immunogenicity of an inactivat…
akhirnya hasil uji klinis sinovac fase 1 dan 2 keluar di jurnal akademis. dan hasilnya...hmmm tanya pakarnya aja langsung 👉mas @septian sementara itu NKRI HARGA MATI udah bayar dp 507m buat vaksin sinovac.
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
RT @hildabast: Sinovac's CoronaVac: phase 1/2 trial published in The Lancet. It's 144 people in phase 1 & 600 in phase 2. There was an earl…
RT @hildabast: Sinovac's CoronaVac: phase 1/2 trial published in The Lancet. It's 144 people in phase 1 & 600 in phase 2. There was an earl…
Sinovac's CoronaVac: phase 1/2 trial published in The Lancet. It's 144 people in phase 1 & 600 in phase 2. There was an earlier preprint reporting on those 600. https://t.co/ZdGMytgB3m Good to see the blanks being filled in... 🤞for phase 3 results.
"Taking safety, immunogenicity, and production capacity into account, the 3 μg dose of #CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials." #China @TheLancetInfDis
Researchers highlight the, "primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population)." (2/3) #China @TheLancetInfDis #CoronavirusPandemic https://
This article from @TheLancetInfDis looks at the "safety, tolerability, and immunogenicity of an inactivated #SARS_CoV_2 vaccine in healthy adults aged 18–59 years." (1/3) #COVID19 #China https://t.co/W4MyDqIY59
RT @Lobo_Lele: Boas novas sobre as fases I e II da coronavac: a vacina é segura, sem efeitos adversos graves e induz anticorpos neutralizan…
@CGTNOfficial @TheLancet Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Yanjun Zhang, Gang Zeng, Hongxing Pan, Chang
RT @septian: Just published in Lancet Infectious Diseases: Sinovac phase 1/2 results Safety, tolerability & immunogenicity of an inactivat…
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li et al Nov 17 https
Boas notícias!
RT @septian: Just published in Lancet Infectious Diseases: Sinovac phase 1/2 results Safety, tolerability & immunogenicity of an inactivat…
@oatila "A eficácia protetora do CoronaVac ainda precisa ser determinada." Link: https://t.co/CcxE6zgvUf https://t.co/Wih24GUT4k
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
RT @josegallucci: 👉CoronaVac tem seus resultados de fase I e II publicados. Safety, tolerability, and immunogenicity of an inactivated SAR…
Saiu a publicação com os resultados da fase 1 e 2 da Coronavac. 97% dos participantes tiveram produção de anticorpos. Aguardando os resultados da fase 3 https://t.co/06hi8VICI7
RT @josegallucci: 👉CoronaVac tem seus resultados de fase I e II publicados. Safety, tolerability, and immunogenicity of an inactivated SAR…
Coronavac produz anticorpos contra a covid em 97% dos participantes, segundo um artigo publicado hoje na revista científica Lancet Infectious Diseases. *Fase 1 e 2* https://t.co/ZBvEjkw9nv
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases - https://t.co/XvOjnGEuPR
Hasil fase 1/2 sinovac @aul_suwantika https://t.co/RbA8WP2tf3
New in @TheLancetInfDis> Safety, tolerability, and immunogenicity of an inactivated #SARSCoV2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial #COVID19 https://t.co/edGOPnvV3C
RT @fabricamargo: Essas vacinas todas com >90% tão me dando um quentinho no coração https://t.co/vsECZ13NYv
Essas vacinas todas com >90% tão me dando um quentinho no coração https://t.co/vsECZ13NYv
Just published in Lancet Infectious Diseases: Sinovac phase 1/2 results Safety, tolerability & immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical t
RT @josegallucci: 👉CoronaVac tem seus resultados de fase I e II publicados. Safety, tolerability, and immunogenicity of an inactivated SAR…
RT @josegallucci: 👉CoronaVac tem seus resultados de fase I e II publicados. Safety, tolerability, and immunogenicity of an inactivated SAR…
👉CoronaVac tem seus resultados de fase I e II publicados. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial https://t.
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
ATENÇÃO: #CORONAVAC produz anticorpos contra a covid em 97% dos participantes. Acesse o artigo @TheLancet https://t.co/k45oOCVJLs
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial https://t.co/enK5TOPw93
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
RT @Lobo_Lele: Boas novas sobre as fases I e II da coronavac: a vacina é segura, sem efeitos adversos graves e induz anticorpos neutralizan…
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
RT @Lobo_Lele: Boas novas sobre as fases I e II da coronavac: a vacina é segura, sem efeitos adversos graves e induz anticorpos neutralizan…
Boas novas sobre as fases I e II da coronavac: a vacina é segura, sem efeitos adversos graves e induz anticorpos neutralizantes mesmo na concentração mais baixa testada. Isso é excelente, pois mais pessoas podem ser vacinadas com o mesmo volume de produção
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
RT @fedkukso: La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de antic…
Pour ceux que ça intéresse les résultats préliminaires phase I/II du coronavac ( chinois mais pas celui testé au Maroc ) testé au Brésil et en Indonésie https://t.co/L1EdTN4Lwu
No. Nos matés la esperanza
Mañana publicaré un artículo sobre esto, pero... los chinos estaban muy callados: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: clinical trial - The Lancet Infectious Diseases https://t.co
La vacuna experimental "CoronaVac" de Sinovac Biotech (China) desencadenó una respuesta inmune rápida, pero el nivel de anticuerpos producidos fue más bajo que en las personas que se habían recuperado de la enfermedad. Resultados Fase I/II en The Lancet: h
$MRNA $BNTX $PFE https://t.co/YX81evD4Yx